Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you are unlikely to be protected if something goes wrong.

Take two mins to learn more

MarraBio

MarraBio

MarraBio

A pioneer in engineering multimeric proteins, MarraBio utilises a proprietary E. coli-based technology for a diverse number of applications. From cell culture reagents to low-cost growth factors for cultivated meat production, MarraBio is poised to make a profound impact in the biotechnology arena.

A pioneer in engineering multimeric proteins, MarraBio utilises a proprietary E. coli-based technology for a diverse number of applications. From cell culture reagents to low-cost growth factors for cultivated meat production, MarraBio is poised to make a profound impact in the biotechnology arena.

A photo of gloved hands holding a synthetic protein sample in a petri dish
A photo of gloved hands holding a synthetic protein sample in a petri dish
A cellular level close up of synthetic proteins

Why did we invest in

Why did we invest in

MarraBio

MarraBio

?

?

  • Enabling protein platform: MarraBio’s proprietary Caf1 technology enables low-cost, high-performance multimeric proteins for cell culture, cultivated meat, and therapeutics.

  • Targeting high value sectors: Focused on high-growth markets demanding biomaterials—cell culture reagents and cultivated meat.

  • Defensive IP: Spun out from decades of Newcastle Uni research; holds exclusive patents in the US and Japan.

  • Scalable & animal-free: E. coli-based bioprocessing delivers cost-effective, sustainable, and scalable manufacturing.

  • Strong exit potential: strong return profile, with clear revenue, licensing, and M&A exit opportunity in a highly acquisitive space.

Get in Touch with Our Team.

Get in Touch with Our Team.

Get in Touch with Our Team.

EverQuest Capital Partners Logo

Transforming

industry.

Creating

legacy.

Subscribe to Newsletter

By subscribing you agree that the email provided is subject to our Privacy Policy.

Copyright ©2026. EverQuest Capital Partners

EverQuest Capital Partners LLP; registered in England and Wales (number OC453092).
Authorised and regulated by the Financial Conduct Authority (FRN: 1044826).

Site design by

EverQuest Capital Partners Logo

Transforming

industry.

Creating

legacy.

Subscribe to Newsletter

By subscribing you agree that the email provided is subject to our Privacy Policy.

Copyright ©2026. EverQuest Capital Partners

EverQuest Capital Partners LLP; registered in England and Wales (number OC453092).
Authorised and regulated by the Financial Conduct Authority (FRN: 1044826).

Site design by

EverQuest Capital Partners Logo

Transforming

industry.

Creating

legacy.

Subscribe to Newsletter

By subscribing you agree that the email provided is subject to our Privacy Policy.

Copyright ©2026. EverQuest Capital Partners

EverQuest Capital Partners LLP; registered in England and Wales (number OC453092).
Authorised and regulated by the Financial Conduct Authority (FRN: 1044826).

Site design by